Michael initially joined Glaxo/GlaxoWellcome/GSK (1989-2002) and was involved in several projects targeting virology, cancer and inflammation with a strong focus in the kinase field.  Upon moving to Scynexis (2002) he oversaw the build up of a successful Discovery CRO group while also leading projects in the fungal, viral and mitochondrial protection, resulting in the discovery of a new antifungal drug (ibrexafungerp).  In 2016 Michael assumed a role as CSO of Cypralis Ltd where his work led to the discovery of CC4066 as a new mitochondrial protectant for organ preservation.  Since 2020, Michael has collaborated on the CURE-PRO technology to design new protein degraders with properties suitable for development.